Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, 1829-1832

Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose Erythromycin

SHOJI KUDOH, ARATA AZUMA, MASAHIKO YAMAMOTO, TAKATERU IZUMI, and MASAYUKI ANDO

Fourth Department of Internal Medicine, Nippon Medical School, Tokyo; Medical School, Nagoya City University, Nagoya; Chest Disease Research Institute, Kyoto University, Kyoto; First Department of Internal Medicine, Kumamoto University, Kamamoto; and Research Group of Diffuse Pulmonary Disease Committee Organized by Ministry of Health and Welfare of Japan, Tokyo, Japan

Diffuse panbronchiolitis (DPB) is a chronic inflammatory disease of the airways with a high rate of mortality despite treatment with a combination of antibiotics and the use of supportive therapy such as oxygen administration. Low-dose erythromycin therapy (EM) (400 to 600 mg/d) has been found to improve the survival of patients with DPB, and most patients with DPB in Japan have been treated with this erythromycin regime since 1984. The purpose of this study was to evaluate the effects of treatment with erythromycin on the survival rate of patients with DPB in Japan. We compared the survival rates of 498 patients with DPB after dividing them into three groups according to the date of their first medical examination (Group a: 1970-1979, Group b: 1980-1984, Group c: 1985-1990). DPB had been diagnosed in these patients using the criteria of the Ministry of the Health and Welfare Diffuse Lung Disease Committee (MHW-DLDC), which includes chronic productive cough, shortness of breath, presence of roentgenologically smoldering symmetrical granular shadows in the middle and lower lung fields, limitation of airflow without decrease in DL_CO, elevated serum cold hemagglutinin titers, and/or narrowing bronchiolus with infiltration of lymphocytes and foamy alveolar macrophages. These patients were registered in the DPB research group of the Ministry of Health and Welfare (MHW). Survival rates were statistically compared using the generalized-Wilcoxon test. The survival rate of Group c was significantly higher than that of Groups a (p < 0.0001) and b (p < 0.0001). In Group c, eight of 87 patients died; five died in the EM nontreated subgroup (n = 24), and three died in the EM-treated subgroup (n = 63). There was a significant difference in the survival rates between the two subgroups in Group c (p < 0.001). Treatment with EM was associated with a significant improvement in the rate of survival of patients with DPB. The efficacy of EM treatment increased the survival rate of patients with DPB, which was more significant in the older than in the younger patients.

This article has been cited by other articles:

				P. A. J. Crosbie and M. A. Woodhead Long-term macrolide therapy in chronic inflammatory airway diseases Eur. Respir. J., January 1, 2009; 33(1): 171 - 181. [Abstract] [Full Text] [PDF]

				H. Ishimoto, H. Mukae, N. Sakamoto, M. Amenomori, T. Kitazaki, Y. Imamura, H. Fujita, H. Ishii, S. Nakayama, K. Yanagihara, et al. Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin J. Antimicrob. Chemother., January 1, 2009; 63(1): 109 - 114. [Abstract] [Full Text] [PDF]

				T. A. R. Seemungal, T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, R. J. Sapsford, and J. A. Wedzicha Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1139 - 1147. [Abstract] [Full Text] [PDF]

				T. Tsuda, C. Ishikawa, H. Konishi, Y. Hayashi, N. Nakagawa, M. Matsuki, H. Mizutani, and K. Yamanishi Effect of 14-Membered-Ring Macrolides on Production of Interleukin-8 Mediated by Protease-Activated Receptor 2 in Human Keratinocytes Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1538 - 1541. [Abstract] [Full Text] [PDF]

				N. Hoffmann, B. Lee, M. Hentzer, T. B. Rasmussen, Z. Song, H. K. Johansen, M. Givskov, and N. Hoiby Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr / Mice Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3677 - 3687. [Abstract] [Full Text] [PDF]

				K. Ishizawa, T. Suzuki, M. Yamaya, Y. X. Jia, S. Kobayashi, S. Ida, H. Kubo, K. Sekizawa, and H. Sasaki Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L565 - L573. [Abstract] [Full Text] [PDF]

				A Bush How has research in the last five years changed my clinical practice? Arch. Dis. Child., August 1, 2005; 90(8): 832 - 836. [Abstract] [Full Text] [PDF]

				L. Saiman, B. C. Marshall, N. Mayer-Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette, A. Y. Fieberg, F. J. Accurso, and P. W. Campbell III Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa: A Randomized Controlled Trial JAMA, October 1, 2003; 290(13): 1749 - 1756. [Abstract] [Full Text] [PDF]

				Y. Kaneko, K. Yanagihara, M. Seki, M. Kuroki, Y. Miyazaki, Y. Hirakata, H. Mukae, K. Tomono, J.-i. Kadota, and S. Kohno Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L847 - L853. [Abstract] [Full Text] [PDF]

				T. Yamaryo, K. Oishi, H. Yoshimine, Y. Tsuchihashi, K. Matsushima, and T. Nagatake Fourteen-Member Macrolides Promote the Phosphatidylserine Receptor-Dependent Phagocytosis of Apoptotic Neutrophils by Alveolar Macrophages Antimicrob. Agents Chemother., January 1, 2003; 47(1): 48 - 53. [Abstract] [Full Text] [PDF]

				T. Kobayashi, K. Tateda, T. Matsumoto, S. Miyazaki, A. Watanabe, T. Nukiwa, and K. Yamaguchi Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate J. Antimicrob. Chemother., July 1, 2002; 50(1): 59 - 66. [Abstract] [Full Text] [PDF]

				T. Kikuchi, K. Hagiwara, Y. Honda, K. Gomi, T. Kobayashi, H. Takahashi, Y. Tokue, A. Watanabe, and T. Nukiwa Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-{kappa}B transcription factors J. Antimicrob. Chemother., May 1, 2002; 49(5): 745 - 755. [Abstract] [Full Text] [PDF]

				K. Yanagihara, K. Tomono, Y. Imamura, Y. Kaneko, M. Kuroki, T. Sawai, Y. Miyazaki, Y. Hirakata, H. Mukae, J.-I. Kadota, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model J. Antimicrob. Chemother., May 1, 2002; 49(5): 867 - 870. [Abstract] [Full Text] [PDF]

				Y. Tsuchihashi, K. Oishi, H. Yoshimine, S. Suzuki, A. Kumatori, T. Sunazuka, S. Omura, K. Matsushima, and T. Nagatake Fourteen-Member Macrolides Suppress Interleukin-8 Production but Do Not Promote Apoptosis of Activated Neutrophils Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1101 - 1104. [Abstract] [Full Text] [PDF]

				L. Saiman, Y. Chen, P. S. Gabriel, and C. Knirsch Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1105 - 1107. [Abstract] [Full Text] [PDF]

				R. Nau and H. Eiffert Modulation of Release of Proinflammatory Bacterial Compounds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis Clin. Microbiol. Rev., January 1, 2002; 15(1): 95 - 110. [Abstract] [Full Text] [PDF]

				M. Gorrini, A. Lupi, S. Viglio, F. Pamparana, G. Cetta, P. Iadarola, J. C. Powers, and M. Luisetti Inhibition of Human Neutrophil Elastase by Erythromycin and Flurythromycin, Two Macrolide Antibiotics Am. J. Respir. Cell Mol. Biol., October 1, 2001; 25(4): 492 - 499. [Abstract] [Full Text] [PDF]

				T. Suzuki, M. Yanai, M. Yamaya, T. Satoh-Nakagawa, K. Sekizawa, S. Ishida, and H. Sasaki Erythromycin and Common Cold in COPD Chest, September 1, 2001; 120(3): 730 - 733. [Abstract] [Full Text] [PDF]

				G. Yamada, T. Igarashi, E. Itoh, H. Tanaka, K. Sekine, and S. Abe Centrilobular Nodules Correlate With Air Trapping in Diffuse Panbronchiolitis During Erythromycin Therapy Chest, July 1, 2001; 120(1): 198 - 202. [Abstract] [Full Text] [PDF]

				A. Azuma, Y. Li, J. Usuki, A. Aoyama, T. Enomoto, and S. Kudoh Fourteen-Membered Ring Macrolides Inhibit Vascular Cell Adhesion Molecule-1 Messenger RNA Induction Preventing Neutrophil-Induced Lung Injury and Fibrosis in Bleomycin-Challenged Mice Chest, July 1, 2001; 120(2007): 20S - 22S. [Full Text] [PDF]

				H. NAKANO, H. IDE, M. IMADA, S. OSANAI, T. TAKAHASHI, K. KIKUCHI, and J. IWAMOTO Reduced Nasal Nitric Oxide in Diffuse Panbronchiolitis Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2218 - 2220. [Abstract] [Full Text]

				A. BUSH, H. TIDDENS, and M. SILVERMAN Clinical Implications of Inflammation in Young Children Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): S11 - 14. [Full Text] [PDF]

				N. KEICHO, K. TOKUNAGA, K. NAKATA, Y. TAGUCHI, A. AZUMA, M. BANNAI, M. EMI, N. OHISHI, Y. YAZAKI, and S. KUDOH Contribution of HLA Genes to Genetic Predisposition in Diffuse Panbronchiolitis Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 846 - 850. [Abstract] [Full Text] [PDF]